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Background: Since the burden of care for elderly patients with heart failure (HF) can be decreased by therapeutic
measures, it is important that such patients are identified correctly. This study explores the prevalence of HF in
nursing homes in Sweden, with special consideration of the risk of failure to diagnose HF in the study population.
A second aim is to explore medication and the adherence to guidelines for the treatment of HF.
Methods: 429 patients from 11 nursing homes were included during 2008–2011. Information about diagnoses and
medications from patient records, blood samples, questionnaire responses and blood pressure measurements were
collected. The baseline characteristics of the patients, their medications and one-year mortality were identified and
then compared regarding HF diagnosis and B-type natriuretic peptide (BNP) levels. A BNP level of >100 ng/L was
used to identify potential cases of HF.
Results: The point prevalence of HF diagnosis in the medical records in the study population was 15.4%. With the
recommended cut-off value for BNP, up to 196 subjects in the study population (45.7%) qualified for further screen-
ing of potential HF.
The subjects in the HF and non-HF groups were similar with the exception of mean age, BNP levels and Mini Men-
tal State Examination results which were higher in the HF group, and the eGFR and blood pressure, which were
lower when HF. The subjects with higher BNP values were older and had lower eGFR, Hb, diastolic blood pressure
and BMI. The subjects with HF diagnoses were in many cases not treated according to the guidelines. Loop di-
uretics were often used without concomitant ACE inhibitors or angiotensin receptor blockers. The subjects without
HF diagnoses in the medical records at inclusion but with BNP values >100 ng/L had less appropriate HF medica-
tion. The one-year mortality was 52.9% in the population with HF.
Conclusions: Our study suggests that the estimated prevalence of HF in nursing homes in Sweden would increase
if BNP measurements were used to select patients for further examinations. The pharmacological treatment of HF
varied substantially, as did adherence to guidelines.Background
The prevalence of HF varies around the world, because
of different panorama of diseases, survival after myocar-
dial infarctions, incidence of valvular heart diseases and
the rate of prevention measures. Epidemiologic studies
from the developing countries are however lacking. The
general prevalence of HF is estimated to be around 1-2%
in the western world [1]. The prevalence of HF rises
with age and persons younger than 50 years are hardly
ever found to have HF. In the US, the prevalence of HF* Correspondence: beata.borgstrom-bolmsjo@med.lu.se
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reproduction in any medium, provided the oris about 0.7% in the 45–54 years of age and 8.4% for
those aged 75 years and older [2].
The prevalence of HF in the elderly is hard to estimate
accurately because of both the atypical presentation of HF
in elderly patients and the lack of large studies in this
population [3,4]. Studies on elderly persons in Europe
show a prevalence of HF from 23% in nursing home resi-
dents in the Netherlands [5] up to almost 50% in 87–
89 year olds in the UK [3]. In Sweden a population-based
study from 2001 show a HF prevalence of 6.7% in men
and women at the age of 75 [6]. There is no updated study
on the prevalence of HF in the elderly population over
75 years of age in Sweden.l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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world. The part of the population aged 65 and over in
Sweden is around 20% corresponding to 1.8 million
people [7]. The proportion older elderly i.e. over 80 years
of age is continually rising and is presently 5.2% [7] and
expected to increase to one tenth of the population in
2050 [8].
The first evaluation of HF should be based on a well-
conducted anamnesis followed by a thorough physical
examination and appropriate laboratory tests [4]. Symp-
toms such as fatigue, confusion, memory deficit, irritabil-
ity, anorexia and a gradual reduction in level of activity
are common manifestations of HF in individuals aged
above 80 years [4]. Dementia is common in nursing home
populations, and a careful medical history, which is crucial
for the diagnosis of HF, may be difficult in residents with
cognitive impairment. It was therefore suggested that the
diagnosis of HF in this group of patients is inadequate [9].
The great variability in the detection and interpretation
of signs and symptoms by physicians is associated with
low sensitivity and specificity in the clinical diagnosis of
HF in the elderly [10]. In nursing homes, adherence to
guidelines for diagnostic investigations and treatment is
notoriously lax [11].
The recommended treatment of HF in the elderly is
similar to that of younger cohorts with respect to renal
function and the risk of polypharmacy. Not many clin-
ical trials have been conducted on elderly patients. How-
ever, the benefit of adherence to treatment guidelines for
HF is evident as it reduces the morbidity and mortality
in elderly patients, as well as in younger patients [12].
β-type natriuretic peptide (BNP) is a hormone produced
mainly by ventricular cardiomyocytes. Its secretion is as-
sociated with stretching of myocardial fibres. Quantitative
analysis of plasma concentrations of BNP is useful to help
confirming the diagnosis, provide a prognosis and guide
treatment in patients with HF [4,13]. BNP cannot be used
to replace cardiac imaging to confirm a final diagnosis
[10]. The use of BNP as a prognostic marker in patients
with HF has proved to be essential for identifying frail eld-
erly patients at risk of events as hospitalization [11]. There
are several different confounders involved in the interpret-
ation of BNP as the BNP levels are shown to rise with age,
female sex and impaired renal function [14]. The studies
of the use of BNP for further diagnosis of HF in an elderly
population are limited.
In Sweden 5.2% of the persons aged 65 and over live
permanently in nursing homes [15]. Elderly living in
nursing homes in Sweden are frail and have several co-
morbidities along with polypharmacy [16]. These indi-
viduals are taken care of by a permanent nursing home
physician who usually visits the nursing home once
weekly. Hence, the elderly do not have to go to the hos-
pital for examinations as the doctor comes to them. Thepatients only go to the hospital when acute illness or trau-
mas with need of hospital care. It is therefore important
for the physician to carefully select the patients in need of
further examinations as echocardiography. If BNP mea-
sures could be used, one would be able to minimize un-
necessary examinations for this frail population.
The aim of this study is to explore the prevalence of
HF in nursing homes in Sweden, with special consider-
ation of the risk of neglected HF diagnoses, by use of
BNP measurements. A second aim is to explore medica-




The Study of Health and Drugs in the Elderly (SHADES)
is a longitudinal cohort study of elderly people living in
11 different nursing homes in three cities in the south-
ern part of Sweden (Linköping, Jönköping and Eslöv).
The aim of the SHADES study is to map the mortality,
morbidity and pharmaceutical treatment of elderly resi-
dents in nursing homes and to use the data collected to
improve health care in the elderly [17]. One of the major
objectives for the SHADES study is to further explore
HF in a nursing home population.
All residents of the 11 selected nursing homes were in-
vited to join the study and when included residents
moved or died, the next person moving in to the nursing
home was asked to participate. During 2008–2011, 429
patients were included in the SHADES study. The mean
age of the participants was 85.0 years with a range be-
tween 65 and 101 years. Patients who lived at the nursing
home temporarily for short-term rehabilitation or pallia-
tive care were excluded. Persons with language difficulties
and persons under the age of 65 were also excluded.
The subjects included, and those subjects who were
excluded, moved or died, are presented in Figure 1.
There are no regional differences regarding nursing
homes within Sweden.
Methods of investigation
Participants were examined at baseline of the study by
specially trained nurses who also collected data from pa-
tient records for diagnoses and current medical treat-
ment. In this study we followed the patients during one
year after inclusion to get one-year mortality data.
Diagnoses collected from the patients records were
coded according the Swedish version of the 10th version
of the International Classification of Diseases (ICD-10)
[18]. The subjects with the ICD-10 code I50 in their pa-
tient record at inclusion were selected as patients with
HF diagnoses.
The in-person testing of participants included meas-












Figure 1 Flow chart of the patients in the SHADES study.
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the study nurses with assistance of the staff at the nurs-
ing home. Blood pressure was measured three times
with one minute apart, in the right arm with the re-
spondent sitting. The mean value of these three mea-
surements was used for blood pressure analyses.
To measure cognitive function, the Mini Mental State
Examination (MMSE) was used [19]. The MMSE con-
sists of 21 questions that measure orientation, memory,
naming, constructional ability and attention. The scores
range from 0 to 30, with a score of 23 or lower indicat-
ing cognitive dysfunction.
Blood samples were drawn according to a standard
procedure and were stored at -70°C in a freezer. All blood
samples were analysed at the hospital in Jönköping by
high-pressure liquid chromatography.
For BNP measurements, a cut off value of 100 ng/L is
suggested to have a satisfactory negative predictive value
and satisfactory sensitivity for determining the need for
further investigation of HF in primary health care [20].
A chemiluminescent micro particle assay (CMIA:
Architect i2000 BNP assay, Abbot Laboratories, Abbot
Park, IL, USA) was used for the quantitative determination
of BNP concentrations in EDTA plasma. The results from
the laboratory analyses are presented in ng/L, with the
method range of 10–5000 ng/L, <10 ng/L and >5000 ng/L,
and the reference value set to <100 ng/L [21].
We used the formula for assessing renal function by
estimating glomerular filtration rate (GFR) according torecently updated Swedish guidelines [22]. The estimated
GFR (eGFR) was defined as the average of (1) the GFR
estimated from creatinine based on the revised equations
for estimating GFR from the Lund-Malmo Study cohort
[23] and (2) the GFR estimated from cystatin C [24].
The HF prevalence in the cohort was calculated as the
point prevalence where the amount of patients with the
ICD-10 diagnosis HF in their patient record at the time
for inclusion was divided by the total amount of subjects
at inclusion.
The patients’ medical treatment was reviewed with re-
spect to current Swedish [25] and European [26] guide-
lines. ACE inhibitors are recommended in the first
instance (angiotensin receptor blockers (ARBs) are rec-
ommended in cases of intolerance to ACE inhibitors),
preferably combined with Beta-blockers, followed by a
mineralocorticoid/aldosterone receptor antagonist (e.g.
spironolactone) when symptoms persist. Digoxin is add-
itionally recommended to control the ventricular rate in
patients with an inadequate response to Beta-blocker
treatment. Diuretics are additionally recommended in
patients with signs and symptoms of congestion.
One-year mortality was calculated by number of
deaths over number of person-year lived over one year.
The subjects who joined the study at the latest period of
inclusion were followed at least 12 months after inclu-
sion to get adequate mortality data. For mortality com-
parisons the population was divided into age strata,
gender and HF diagnosis.
Ethics
The study protocol was approved by the Regional Ethics
Review Board at Linköping University (date: October 18,
2007; case number M150-07). Informed consent was ob-
tained from all participants. If the patient could not
understand the information and give informed consent
this was obtained from next of kin.
Statistical analysis
The data collected in the study were analysed using the
SPSS Statistics 20 (SPSS, Inc. Chicago, IL). Differences
between groups were tested using Student’s T-test and
the Mann–Whitney U test for continuous variables and
the Chi-square test for discrete variables.
For calculating differences between several groups the
one-way ANOVA test was done for continuous variables
and Chi square test for discrete variables, using the
Bonferroni correction for mass significance. With the
Bonferroni calculation for mass significance when six
comparisons were made, the p value for significant dif-
ferences was corrected from p < 0.05 to p <0.0083.
Binary logistic regression analysis with the Enter method
was made for observing differences between the groups
with HF diagnosis and the group with no HF diagnosis
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gression model was tested with the Hosmer and Leme-
show test, and with Nagelkerke R2.
Results
Baseline characteristics
The point prevalence of diagnoses of HF in the patient
records at the time for inclusion was 15.4% in our study
population. The characteristics of the subjects in the
group with HF diagnoses, compared to the subjects with-
out HF diagnoses, are shown in Table 1. The subjects in
the two groups were quite similar. The population with
HF diagnoses was older than the population without HF
diagnoses (86.8 compared to 84.7 years p = 0.024). The
BNP values were higher and eGFR as well as blood pres-
sure were lower in the group with HF diagnoses. The
group with diagnosed HF had significantly higher MMSE
scores compared to the group without diagnosed HF. The
prevalence of hypertension was similar in both groups.
BNP
The study population was divided into quartiles based
on BNP level and the characteristics of the subjects in
the four groups are presented in Table 2. Only 32% of
the subjects in the fourth BNP quartile had been diagnosed
with HF. The MMSE results did not differ between the dif-
ferent quartiles. The prevalence of hypertension did not




Point prevalence of HF diagnosis (%) 15.4
BNP range (ng/L) 10-4200
(n = 402)
Median 103.5
BNP (ng/L) mean ± SD 181.1 ± 299.6
Male sex n (%) 124 (28.9)
Age (years) mean ± SD 85.0 ± 7 (n = 429)
P-glucose (mmol/L) mean ± SD 5.6 ± 1.9 (n = 390)
hs-CRP (mg/L) mean ± SD 3.8 ± 2.6 (n = 266)
TSH (mIE/L) mean ± SD 2.0 ± 2.5 (n = 406)
Hb (g/L) men mean ± SD 128.5 ± 15.4 (n = 115)
Hb (g/L) women mean ± SD 124.5 ± 13.6 (n = 276)
eGFR (ml/min/1.73 m2) mean ± SD 44.4 ± 16.6 (n = 406)
BMI (kg/m2) mean ± SD 24.9 ± 5.6 (n = 420)
MMSE result mean ± SD 17.1 ± 6.5 (n = 359)
Systolic blood pressure (mmHg) mean ± SD 133.5 ± 23.4 (n = 407)
Diastolic blood pressure (mmHg) mean ± SD 72.2 ± 11.7 (n = 407)
Hypertension n (%) diagnosis 128 (29.8)between the quartiles differed in Hb, blood pressure, eGFR,
thyroid-stimulating hormone (TSH), and body mass index
(BMI), as well as for age (p < 0.05) (Table 2).
Based on the recommended BNP cut-off for HF
of >100 ng/L, 196 subjects in the study population may
have had HF, while only 66 had the diagnosis in the
medical charts. In the group with no HF diagnosis at the
time for inclusion the mean BNP level was 143.2 ng/L,
and 154 subjects in this group should have been further
examined for potential HF.
High BNP values but no HF
The study population was divided into those with HF
diagnosis in the medical record at inclusion and those
with no HF diagnosis but with BNP values >100 ng/L.
This is presented in Table 3.
Pharmaceutical treatment
The patients with diagnosed HF used more drugs than the
subjects without HF diagnoses but with BNP > 100 ng/L
(8.5 vs. 7.0 medications on average, p < 0.001). The most
commonly used medications were loop diuretics followed
by Beta-blockers in the HF group (used in 75.8% and 59.1%
of the subjects respectively) and Beta-blockers followed by
loop diuretics in the non-HF group with BNP > 100 ng/L
(used in 45.5% and 32.5% of the subjects respectively).
Treatment with ACE inhibitors/ARBs were used in 50% of
the subjects with HF diagnosis and in 14.9% in subjectsgnoses compared to the population with no diagnosis
No HF diagnosis HF diagnosis p value
(n = 363) (n = 66) HF vs. no HF
- 100
10-1487 30-4200 p = 0.002
(n = 342) (n = 60)
Median 89.5 Median 210.5 p < 0.001
143.2 ± 178.6 397.4 ± 608.1 p = 0.002
104 (28.7) 20 (30.3) p = 0.79
84.7 ± 7.1 (n = 363) 86.8 ± 5.6 (n = 66) p = 0.024
5.6 ± 1.9 (n = 332) 5.6 ± 1.7 (n = 58) p = 0.81
3.8 ± 2.6 (n = 232) 4.2 ± 2.8 (n = 34) p = 0.32
2.1 ±2.6 (n = 343) 1.8 ± 1.4 (n = 63) p = 0.40
129.4 ± 14.3 (n = 97) 123.8 ± 20.1 (n = 18) p = 0.16
124.9 ± 13.4 (n = 236) 121.9 ± 14.2 (n = 40) p = 0.19
45.9 ± 15.5 (n = 344) 35.9 ± 16.4 (n = 62) p < 0.001
24.8 ± 4.9 (n = 355) 25.5 ± 5.8 (n = 65) p = 0.30
16.8 ± 6.4 (n = 299) 18.6 ± 6.7 (n = 60) p = 0.061
134.5 ± 23.5 (n = 344) 127.9 ± 21.8 (n = 63) p = 0.038
72.7 ± 11.7 (n = 345) 69.4 ± 11.6 (n = 62) p = 0.040
108 (29.8) 20 (30.3) p = 0.93
Table 2 Baseline characteristics of the study population, divided into quartiles based on BNP
BNP quartile 1 2 3 4 p value
BNP range (ng/L) 10-51 52-102 103-191 192-4200
(n = 100) (n = 101) (n = 101) (n = 100)
BNP (ng/L) mean ± SD 31.2 ± 10.9 74.8 ± 14.4 148.7 ± 24.7 471.2 ± 492.3 p < 0.001
(n = 100) (n = 101) (n = 101) (n = 100) b, c, e, f
Male sex (%) 35 (n = 35) 26.7 (n = 27) 29.7 (n = 30) 26 (n = 26) p = 0.49
Age (years) mean ± SD 81.1 ± 7.3 84.8 ± 6.5 87.1 ± 5.5 87.2 ± 6.1 p < 0.001
(n = 100) (n = 101) (n = 101) (n = 100) a, b, c
P-glucose (mmol/L) mean ± SD 6.0 ± 2,5 5.5 ± 1.5 5.6 ± 1.6 5.5 ± 1.7 p = 0.21
(n = 96) (n = 95) (n = 99) (n = 95)
hs CRP (mg/L) mean ± SD 3.7 ± 2.8 4.0 ± 2.7 3.5 ± 2.5 4.2 ± 2.6 p = 0.22
(n = 68) (n = 67) (n = 68) (n = 59)
TSH (mIE/L) mean ± SD 2.8 ± 3.8 1.7 ± 1.8 1.9 ± 2.2 1.7 ± 1.1 p = 0.003
(n = 100) (n = 99) (n = 101) (n = 100) a, b, c
BMI (kg/m2) mean ± SD 26.8 ± 5 24.8 ± 4.6 24.0 ± 4.4 23.9 ± 4.8 p < 0.001
(n = 98) (n = 98) (n = 101) (n = 98) a, b, c
eGFR (ml/min/1.73 m2) mean ± SD 51.1 ± 15.2 46.1 ± 14.8 41.0 ± 15.1 39.5 ± 16.3 p < 0.001
(n = 100) (n = 101) (n = 99) (n = 99) b, c, e
Hb in men (g/L) mean ± SDHb in women (g/L) mean ± SD 135.3 ± 13.7 128.7 ± 14.1 125.7 ± 13.9 123.0 ± 17.4 p = 0.010
(n = 35) (n = 25) (n = 29) (n = 25) c
125.2 ± 12.7 125.7 ± 13.0 124.2 ±13.8 122.6 ±14.7 p = 0.54
(n = 63) (n = 72) (n = 68) (n = 70)
Systolic blood pressure (mmHg) mean ± SD 134.8 ± 19.6 132.8 ± 20.7 136.0 ± 26.9 131.3 ± 25.8 p = 0.47
(n = 97) (n = 97) (n = 99) (n = 95)
Diastolic blood pressure (mmHg) mean ± SD 74.0 ± 10.1 73.5 ± 11,5 70.2 ± 12.0 70.7 ± 12.5 p = 0.045
(n = 97) (n = 97) (n = 99) (n = 95)
HF diagnosis n (%) 7 (7) 4 (4) 17 (16.8) 32 (32) p < 0.001
c, d, e
Hypertension diagnosis n (%) 31 (31) 27(26.7) 34 (33.7) 33 (33) p = 0.71
MMSE result mean ± SD 17.0 ± 6.6 17.0 ± 6.6 17.2 ± 7.0 17.2 ± 5.8 p = 0.89
(n = 80) (n = 87) (n = 92) (n = 88)
Significant difference between BNP quartiles 1–4, is presented as:
1 and 2: a.
1 and 3: b.
1 and 4: c.
2 and 3: d.
2 and 4: e.
3 and 4: f.
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with diagnosis of HF were more likely to be treated with
ACE inhibitors/ARBs, Spironolactone and loop diuretics
(Table 3). For the treatment with Digoxin and Beta-
blockers the groups were similar. The subjects with high
BNP values had more medications compared to the sub-
jects with lower BNP values (the average number of
medications per subject was 7.7 for the fourth BNP
quartile and 6.0 in the first BNP quartile). The subjects
in the fourth quartile were more likely to be treated withBeta-blockers, Digoxin and loop diuretics (Table 4). The
groups did not differ in the treatment with ACE inhibi-
tors/ARBs or Spironolactone.
One-year mortality
One-year mortality rate for the study population was
34.2%. One-year mortality rate in the group with diag-
nosed HF was significantly higher compared to the non-
HF patients (52.9% vs. 31.1%, respectively, p = 0.02).
When dividing the groups into gender, the mortality was
Table 3 Logistic regression analysis concerning age, gender, renal function and medications in relation to the
population with HF diagnoses and the population with no diagnosis of HF and BNP > 100 ng/L
Variable HF diagnoses
(n = 66)
No HF diagnoses and BNP >
100 ng/L (n = 154)
p-value OR CI 95% for OR
Age (years) 86.8 ± 5.6 (n = 66) 87.0 ± 6.0 (n = 66) 0.82 1.02 0.94-1.08
Male sex n (%) 20 (30.3) 44 (28.6) 0.91 0.96 0.44-2.10
eGFR (ml/min/1.73 m2) 35.9 ± 16.4 (n = 62) 42.1 ± 15.4 (n = 152) 0.27 0.99 0.96-1.01
ACE inhibitors/ARBs 33 (50) 23 (14.9) <0.001 11.27 3.14-40.41
Beta-blockers 39 (59.1) 70 (45.5) 0.99 1.00 0.48-2.08
Spironolactone 10 (15.2) 8 (5.2) 0.04 3.55 1.08-11.68
Digoxin 16 (24.2) 14 (9.1) 0.31 1.66 0.62-4.43
Furosemide/loop diuretics 50 (75.8) 50 (32.5) <0.001 5.97 2.39-14.92
Loop diuretics with simultaneous ACE inhibitor/ARB treatment 24 (36.4) 35 (22.7) 0.08 0.25 0.05-1.16
Nagelkerke R2 0.34.
Hosmer and Lemeshow test p-value 0.74.
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group, and the difference was also significant when di-
vided into age strata (Table 5).
When comparing the groups with HF diagnosis and
no HF diagnosis but with BNP > 100 ng/L, the mortality
was similar (46.2% vs. 52.8%, p = 0.29).Discussion
The point prevalence of patients with diagnosed HF in
their patient record at baseline was 15.4% but, according
to BNP levels, the prevalence might have been closer to
50% if further examinations had been conducted in sub-
jects with BNP values above the suggested cut-off for








Furosemide/loop diuretics n (%)
Loop diuretics with simultaneous ACE inhibitor/ARB treatment n (%)
Significant difference between BNP quartiles 1–4, is presented as:
1 and 2: a.
1 and 3: b.
1 and 4: c.
2 and 3: d.
2 and 4: e.
3 and 4: f.It is possible that HF diagnosis is neglected in patients
with cognitive impairment as the patients without HF
diagnosis tend to have a lower result on MMSE.
This study is unique in that the population studied is
old and frail, with a mean age of 85 years. In most other
studies of HF, this group is excluded [27]. Over 400 pa-
tients were studied, which provided substantial data for
mapping the study population. Since the patients were
living in nursing homes, the reports of medications and
compliance with medications may have been more reli-
able than in other settings.
A literature review from 2010 showed a HF prevalence
of 20% in elderly patients living in nursing homes [9].
The prevalence of HF was determined in five studies
and the range was 15-20% [28-31], with the exception ofquartiles based on BNP
1 2 3 4 p value
10-51 52-102 103-191 192-4200
n = 100) (n = 101) (n = 101) (n = 100)
14 (14) 20 (19.8) 20 (19.8) 28 (28) 0.11
14 (14) 31 (30.7) 45 (44.6) 54 (54) <0.001
a, b, c, e
9 (9) 4 (4) 7 (6.9) 7 (7) 0.56
2 (2) 1 (1) 13 (12.9) 14 (14) <0.001
b, c, d, e
27 (27) 39.6 (40) 36 (35.6) 50 (50) 0.009
c
6 (6) 15 (14.9) 13 (12.9) 20 (20) 0.034
c
Table 5 One year mortality
No HF (n = 363) HF (n = 66) p value (chi-square)
Women (n = 305) 31.8% 52.3% 0.004
Men (n = 124) 29.4% 54.3% <0.001
Total (n = 429) 31.1% 52.9% 0.002
Age (years)
65-80 (n = 106) 16.8% 85.9% <0.001
81-90 (n = 216) 27.7% 48.4% 0.004
90-101 (n = 107) 58.1% 78.6% 0.001
Patients without HF compared to patients with HF.
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last study, HF was diagnosed after a thorough examin-
ation by a clinical geriatrician, while information from
medical records was used to confirm the diagnosis of HF
in the other four studies [9,28-31]. This suggests that there
are patients with undiagnosed HF that is clinically evident
when the patients are more thoroughly examined.
More thorough examinations and echocardiography
were shown to give HF patients a more accurate diagno-
sis. In a recently published study from the UK [33], the
presence of HF was determined by evaluation of symptoms
and signs, functional capacity, and quality of life, portable
on-site echocardiography, and evaluation of medical re-
cords. The point prevalence of HF in this study was 22.8%,
and additional results showed that most cases of HF were
previously undiagnosed. Moreover, three-quarters of previ-
ously recorded cases were not confirmed.
An on-going Dutch study is investigating the preva-
lence of HF in nursing home residents after a focused
clinical assessment by a geriatrician [34]. This will pro-
vide valuable information concerning undiagnosed HF,
but there might be limitations to the study, such as re-
fusal of eligible patients to participate due to the exten-
sive examinations involved.
Our prevalence of HF diagnoses of around 15% is con-
sistent with several other studies [4,9,34]. However, in
our study about half of the study population had a BNP
value above the cut-off value for HF. In addition, the
prevalence of HF increases with age and one might ex-
pect that the prevalence in this patient sample would be
higher than 15%.
Because of the great cost and hospitalization burden of
HF, screening tests for left ventricular dysfunction among
high-risk subjects (such as frail elderly persons) are re-
quired to enable implementation of intervention protocols
[11]. With the suggested cut-off value for BNP, the nega-
tive predictive value is high and the BNP value should be
used to exclude patients from further examination [20].
Many studies have shown the role of BNP as a predictor
of morbidity [35,36]. This was also the case in this study,
where the frailty (low BMI, low blood pressure, low eGFR)
of patients increased with BNP levels (Table 2). Studiesunderline the confounders of age, gender and an impaired
renal function when using the BNP value for elderly pa-
tients with HF [20,37]. Although in our study, the sub-
jects with BNP values > 100 ng/L without HF diagnosis
did not differ in gender, age nor renal function when
compared to the subjects with HF diagnosis. This could
emphasize the need of further screening of the patients
with BNP values > 100 ng/L with echocardiography to
avoid neglected HF.
Cognitive impairment is a common consequence of
HF [38] and is known to be an independent prognostic
marker for HF outcome since it affects quality of life,
morbidity and mortality [39]. In our study, the MMSE
scores were not significantly different between the first
and the fourth BNP quartile. The individuals with HF
diagnoses had higher scores in the MMSE test compared
to patients without HF diagnoses. The patients with low
MMSE scores may not have been able to express their
symptoms of HF, which could have been one reason why
possible HF diagnoses could have been disregarded.
If correctly diagnosed, HF is a condition in which
pharmacological treatment can increase quality of life
and decrease morbidity [40]. Even though most clinical
trials have included younger persons, the recommenda-
tions for medical treatment of elderly patients with HF
do not differ from the general recommendations. Spe-
cial attention should be paid to co-morbidities, the risk
of polypharmacy and renal function [40]. In this study
population, renal function was not an obstacle for treat-
ment in many patients as the mean eGFR was around
40 ml/min/1.73 m2.
It is important for HF patients to receive the recom-
mended treatment for their condition. In this study, the
probability of adequate medication increased if the cor-
rect diagnosis was in the patient record.
The guidelines recommend ACE inhibitors/ARBs as
the first-line HF treatment, with the use of diuretics as a
complement when there is volume overload [40]. The
proportion of patients receiving ACE inhibitors/ARBs
should therefore ideally have been higher in our study
population, especially considering how common the use
of loop diuretics was. The use of loop diuretics may acti-
vate the renin-angiotensin-aldosterone system [41], which
plays an important role in the progression of HF, and it
may also lower the GFR by decreasing the intravascular
volume. It is also known to cause electrolyte imbalances
[40]. Therefore, routine use of diuretics without signs of
fluid retention should be avoided and has even been
shown to be associated with worse outcomes in patients
with HF [42].
The mortality of the patients with diagnosed HF was
higher than in the non HF group. This underlines that
HF is important to take into concern in the elderly. The
mortality in the group with BNP >100 ng/L was similar
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patients with unrecognised HF in this group.
Limitations of the paper
The study has limitations in that the sample used was
not randomly selected, but rather selected for reasons of
convenience from three different areas in Sweden, with
persons living in nursing homes whose staffs was inter-
ested in joining the project being asked to participate.
The nursing homes included did not differ notably from
other nursing homes in Sweden [17]. There is limited
access to nursing homes in Sweden and consequently
the population in nursing homes reflects the group of
elderly individuals in the society in greatest need of care
[16]. Therefore, the results cannot be generalized to the
overall population in this age group. Another limitation
of the study was the unavailability of the results of echo-
cardiography and electrocardiography, which would have
provided valuable information about subjects with HF.
Conclusions
Our study suggests that the estimated prevalence of HF
in nursing homes in Sweden would be higher if BNP
measurements were used to select patients for further
investigation. The HF diagnosis in subjects with cogni-
tive impairment may in some cases be neglected. The
use of medications in the patients with HF diagnoses
was not in accordance with current guidelines regarding
use of HF medications in elderly individuals.
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